A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)
Simple Imaging Versus Standard Imaging Selection in Stroke Patients for Endovascular Treatment: the NO-SELECT Randomized Trial
Xinqiao Hospital of Chongqing
1,846 participants
Dec 12, 2024
INTERVENTIONAL
Conditions
Summary
Several studies suggest that advanced multi-modal imaging with CTP should be used to screen late time window stroke patients for thrombectomy. However, NCCT is more accessible when comparing with CTP. It is unclear whether the NCCT-based ASPECTS can be used as an imaging criterion to screen patients for thrombectomy. The newly published MR CLEAN-LATE and TENSION trials used NCCT or CTA, but still relied on ASPECTS scores to evaluate and select patients for endovascular therapy. However, different trials have different time windows. The aim of this trial was to assess the clinical outcomes of stroke patients with anterior large vessel occlusion who selected by simple imaging (NCCT) comparing via standard imaging screening strategy (CTP/MRI). The hypothesis is that simple imaging is non-inferior to standard imaging selection strategy in terms of achieving favorable outcomes.
Eligibility
Inclusion Criteria5
- Aged 18 years or older;
- The interval time from last known well to hospital arrival is within 24 hours;
- Acute stroke confirmed by clinical symptoms or imaging examination;
- Field Assessment Stroke Triage for Emergency Destination (FAST ED) ≥4;
- Written informed consent is obtained from patients and/or their legal representatives.
Exclusion Criteria9
- Allergy to radiographic contrast agents, or nitinol devices;
- Currently pregnant or lactating (women patients);
- Arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel;
- Preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;
- Multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation);
- Brain tumors with mass effect (except meningiomas) that are radiographically pleasant;
- Intracranial aneurysm, arteriovenous malformation;
- Any terminal illness with life expectancy less than 6 months;
- Unlikely to be available for 90-day follow-up.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
NCCT and CTA will be used to screen patients for endovascular treatment
NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05230914